Created at	Source	Raw Value	Validated value
Feb. 12, 2022, 3:30 p.m.	usa	Incidence of AESIs and SAEs;Incidence of AESIs and SAEs;Serum anti-SCB-2019 IgG antibody titers;Serum anti-SCB-2019 IgG antibody titers	Incidence of AESIs and SAEs;Incidence of AESIs and SAEs;Serum anti-SCB-2019 IgG antibody titers;Serum anti-SCB-2019 IgG antibody titers
June 23, 2021, 1:30 a.m.	usa	Geometric mean fold rise (GMFR) of serum anti-SCB-2019 IgG antibody titers.;Geometric mean titer (GMT) of serum anti-SCB-2019 IgG antibody titers.;Number of participants with Adverse Event of Special Interest, (AESIs);Number of participants with Serious Adverse Events (SAEs);Seroconversion rate (SCR) of serum anti-SCB-2019 IgG antibody titers.	Geometric mean fold rise (GMFR) of serum anti-SCB-2019 IgG antibody titers.;Geometric mean titer (GMT) of serum anti-SCB-2019 IgG antibody titers.;Number of participants with Adverse Event of Special Interest, (AESIs);Number of participants with Serious Adverse Events (SAEs);Seroconversion rate (SCR) of serum anti-SCB-2019 IgG antibody titers.